Pinar Karaca-Mandic, PhD

Previous studies have found modest uptake of biosimilars in both commercial and Medicare populations. This study finds that the uptake varies between the rural and urban provider settings.

After the CDC guidelines’ release, total opioid marketing spending and encounters per physician decreased, but spending per encounter subsequently increased.

This article presents an evaluation of testosterone marketing practices around the period of the testosterone label warning by physician specialty and rural vs urban primary care service area.

Although previous work has found lower costs for biosimilar filgrastim compared with reference filgrastim, this study found that site of care can change this calculus, reducing savings.

Treatment delays limit the social value generated by chimeric antigen receptor (CAR) T-cell therapy for the treatment of pediatric acute lymphoblastic leukemia and diffuse large B-cell lymphoma.

Medicare formularies were inconsistent in increasing restrictiveness to drugs that received FDA black box warnings for death and/or cardiovascular risk with safer available drug alternatives.

We measured the financial consequences of new CRC treatment regimens. New regimens have increased cost directly through price and indirectly through nonstandard and second-line regimen use.

This study investigates the potential impact of new medical loss ratio regulation on the individual market for health insurance in the United States.

Biologic therapy for rheumatoid arthritis or multiple sclerosis was associated with lower use of some types of medical services within 2 to 3 years of initiation.